First Page | Document Content | |
---|---|---|
Date: 2015-04-22 23:39:46GlaxoSmithKline Glucocorticoids Organofluorides Chronic lower respiratory diseases Chronic obstructive pulmonary disease Fluticasone/salmeterol Formoterol Fluticasone propionate Salmeterol Pulmonology Medicine Respiratory therapy | 7.10 FLUTICASONE+VILANTEROL, dry powder inhaler, fluticasone furoate 100 microgram/actuation + vilanterol (as trifenatate) 25 microgram/actuation, Breo® Ellipta®, GlaxoSmithKline Australia Pty Ltd.Add to Reading ListSource URL: www.pbs.gov.auDownload Document from Source WebsiteFile Size: 50,54 KBShare Document on Facebook |
Case 3:16-cvDocument 1 FiledPage 1 ofDorian S. Berger, CA State Bar NoDaniel P. Hipskind, CA State Bar NoDocID: 1rqYi - View Document | |
Microsoft WordDOCXDocID: 1rnqZ - View Document | |
Beilage 1: ArzneimittelmonographienDocID: 1rinj - View Document | |
SAFETY DATA SHEET Page 1 of Total 6 Date of Issue: August 2016 SDS No. FMC/RAD/1 SECTION 1DocID: 1rdYu - View Document | |
imatinib and colon cancer. imatinib availability imatinib and cml imatinib and tight junction cancer imatinib prostate dercum and imatinib zactima plus imatinibDocID: 1rdbp - View Document |